Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493350 · ClinicalTrials.gov registry record
Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 660
- Enrollment target
NCT00493350: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT00493350 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 660 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00493350 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 660 participants
- Enrollment target
Study Summary
Primary Objectives: 1. To validate the prognostic significance of circulating tumor cells (CTCs) in patients with newly diagnosed metastatic breast cancer (MBC). 2. To prospectively determine if assessment of CTCs can be used to stratify patients with MBC into two prognostic groups independent of existing methods i.e. hormone-receptor status, site of metastasis (e.g. visceral vs. non visceral) and treatment administered (e.g. chemotherapy vs. hormonal therapy). 3. To incorporate this information into the current TNM staging system by sub-classifying stage IV disease into two prognostic groups, Stage IVA and Stage IVB. Secondary Objective: 1\. To perform global gene profiling on selected specimens and correlate the profiles with clinical outcomes.
Interventions
- PROCEDURE Blood Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00493350
The ClinicalTrials.gov registry entry for NCT00493350 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 660 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood Sample is the first listed.
NCT00493350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00493350 about?
NCT00493350 is a clinical study titled "Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer". Primary Objectives: 1. To validate the prognostic significance of circulating tumor cells (CTCs) in patients with newly diagnosed metastatic breast cancer (MBC). 2. To prospectively determine if assessment of CTCs can be used to stratify patients with MBC into two prognostic groups independent of e...
What is the current status of trial NCT00493350?
This trial is currently completed. The enrollment target is 660 participants. The study started on 2005-10. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00493350?
The interventions under investigation include: Blood Sample (PROCEDURE).
Who is sponsoring clinical trial NCT00493350?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.